EGFR mutation + PD-L1 expression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 expression	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
EGFR mutation + PD-L1 expression	Lung Adenocarcinoma	EGFR mutation + PD-L1 expression	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
EGFR mutation + PD-L1 expression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 expression	Non Small Cell Lung Cancer	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR mutation + PD-L1 expression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 expression	Non Small Cell Lung Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3

EGFR mutation + PD-L1 expression

Associations